Cargando…

Metastatic Latency, a Veiled Threat

Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. D...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kangsan, Marquez-Palencia, Mauricio, Malladi, Srinivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691038/
https://www.ncbi.nlm.nih.gov/pubmed/31447846
http://dx.doi.org/10.3389/fimmu.2019.01836
_version_ 1783443283167412224
author Kim, Kangsan
Marquez-Palencia, Mauricio
Malladi, Srinivas
author_facet Kim, Kangsan
Marquez-Palencia, Mauricio
Malladi, Srinivas
author_sort Kim, Kangsan
collection PubMed
description Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. Dynamic interactions between the latent disseminated tumor cells and their surrounding microenvironment aid cancer cell survival and facilitate escape from immune surveillance. Here, we highlight findings from preclinical models that provide a conceptual framework to define and target the latent metastatic phase of tumor progression. The hope is by identifying patients harboring latent metastatic cells and providing therapeutic options to eliminate metastatic seeds prior to their emergence will result in long lasting cures.
format Online
Article
Text
id pubmed-6691038
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66910382019-08-23 Metastatic Latency, a Veiled Threat Kim, Kangsan Marquez-Palencia, Mauricio Malladi, Srinivas Front Immunol Immunology Metastatic relapse is observed in cancer patients with no clinical evidence of disease for months to decades after initial diagnosis and treatment. Disseminated cancer cells that are capable of entering reversible cell cycle arrest are believed to be responsible for these late metastatic relapses. Dynamic interactions between the latent disseminated tumor cells and their surrounding microenvironment aid cancer cell survival and facilitate escape from immune surveillance. Here, we highlight findings from preclinical models that provide a conceptual framework to define and target the latent metastatic phase of tumor progression. The hope is by identifying patients harboring latent metastatic cells and providing therapeutic options to eliminate metastatic seeds prior to their emergence will result in long lasting cures. Frontiers Media S.A. 2019-08-06 /pmc/articles/PMC6691038/ /pubmed/31447846 http://dx.doi.org/10.3389/fimmu.2019.01836 Text en Copyright © 2019 Kim, Marquez-Palencia and Malladi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kim, Kangsan
Marquez-Palencia, Mauricio
Malladi, Srinivas
Metastatic Latency, a Veiled Threat
title Metastatic Latency, a Veiled Threat
title_full Metastatic Latency, a Veiled Threat
title_fullStr Metastatic Latency, a Veiled Threat
title_full_unstemmed Metastatic Latency, a Veiled Threat
title_short Metastatic Latency, a Veiled Threat
title_sort metastatic latency, a veiled threat
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691038/
https://www.ncbi.nlm.nih.gov/pubmed/31447846
http://dx.doi.org/10.3389/fimmu.2019.01836
work_keys_str_mv AT kimkangsan metastaticlatencyaveiledthreat
AT marquezpalenciamauricio metastaticlatencyaveiledthreat
AT malladisrinivas metastaticlatencyaveiledthreat